## **General Information**

Carlo and at				
Scrip code* NSE Symbol*	524075			
	ALBERT			
MSEI Symbol* ISIN*	NOTLIS			
	INE1550			
Type of company	Main Bo	ard		
Class of security	Equity			
Date of start of financial year	01-04-20	)25		
Date of end of financial year	31-03-20	26		
Date of board meeting when results were approved	12-11-20	25		
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	01-11-20	25		
Description of presentation currency	INR			
Level of rounding	Lakhs			
Reporting Type	Quarterly	,		
Reporting Quarter	Second quarter			
Nature of report standalone or consolidated	Standalo	ne		
Whether results are audited or unaudited for the quarter ended	Unaudited			
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited			
Segment Reporting	Single se	ament		
Description of single segment	Pharmaceuticals			
Start date of board meeting	12-11-2025			
Start time of board meeling	11:00:00			
End date of board meeting	12-11-2025			
End time of board meeting	15:40:00			
Whether cash flow statement is applicable on company	true			
Type of cash flow statement	Cash Flow Indirect			
Declaration of unmodified opinion or statement on impact of audit qualification	1			
Whether the company has any related party?	true	а ориноп		
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	true			
We declare that the acceptance of fixed deposits by the bans/Non-Banking inance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	NA		
II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and heir exclusive associations as well as on deposits of Chairman, Chairman & Aanaging Director, Executive Director or such other Executives appointed for fixed tenure.	f NA			
II) Whether the company is a 'high value debt listed entity' according to egulation 15 (1A)?	false			
If answer to above question is Yes, whether complying with proviso to egulation 23 (9), i.e., submitting RPT disclosures on the day of results ublication?				
<ul> <li>i) If answer to above question is No, please explain the reason for not omplying.</li> </ul>				
hether the updated Related Party Transactions (RPT) Policy (in compliance ith Reg. 23 of SEBI LODR) has been uploaded on the website of the ompany?	true			
atest Date on which RPT policy is updated	14-03-202	14-03-2024		
dicate Company website link for updated RPT policy of the Company	https://www.albertdavidi ndia.com/policies.php			
nether statement on deviation or variation for proceeds of public issue,		false		
o. of times funds raised during the quarter				
hether the disclosure for the Default on Loans and Deht Securities is	false	Textual Information		

## Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quar

	Details of the party (listed entity /subsidiary) entering into the transaction			Tun of	Details of	10.00	Remarks		Date of Audit	Value of	In case monies are due to either party as a result of the transaction	
Sr. No.		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	ated party related	transaction as approved by the audit committee	approval by audit committee	ratified by	Meeting where the ratification	period	Opening balance	
	Limited	Gillander Arbuthnot and Company Limited	Company in which KMP/Director has significant influence	Purchase of goods or services		60.00	Not Applicable	24.00	12-02- 2025	24.00	0.00	0.00
		Strategic Marketing Solutions & Research Centre Private Limited	Company in which KMP/Director has significant influence	Purchase of goods or services		35.00	Not Applicable	12.50	12-02- 2025	12.50	0.00	0.00
	Limited	Medclin Research Pvt. Ltd.	Company in which KMP/Director has significant influence	Purchase of goods or services		23.00	Not Applicable	6.48	12-02- 2025	6.48	0.00	0.00
		Kothari Medical Centre	Trust in which KMP has significant influence		Donation Paid		Not Applicable	50.00	12-02- 2025	50.00	0.00	0.00
		IVIF. Arun Kumar	Chairman & Executive Director	Remuneration			Not Applicable	129.86	13-05- 2025	129.86	0.00	0.00
	Albert David	Prabhawati		Any other transaction	Sitting fees		Not Applicable	0.70	12-02- 2025	0.70	0.00	0.00
	limited	Mr. Anand Vardhan	Non-	Any other transaction	Sitting fees		Not Applicable		12-02- 2025	0.50	0.00	0.00
	Albert David F Limited 8	Kothari Phytochemicals   & Industries   Ltd.		transaction	Sale of Equity Shares	500.00	Not Applicable	99.99		99.99	0.00	0.00
	Albert David F Limited T	PDK Family I Trust I	Company in which KMP/Director / has t significant influence	transaction	Sale of Equity Shares	500.00	Not Applicable	14.98	12-02- 2025	14.98	0.00	0.00